Back to search

Article

Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome expression could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti–programmed cell death 1 monotherapy

2023-06-13

Abstract excerpt

<title>Abstract</title><p>Purpose Patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) have proven benefit from anti–programmed cell death 1 (anti-PD-1) monotherapy. Here, we retrospectively analyze the association of plasma Epstein-Barr virus (EBV) DNA load and tumor viral lytic genome with clinical outcome from 2 registered phase I trials. Methods Patients with RM-NPC from Checkmate 077 (nivol...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3f97c1f3-857f-56ce-a22f-101a6723c5c1
DOI
10.21203/rs.3.rs-2934995/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome expression could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti–programmed cell death 1 monotherapyDOI 10.21203/rs.3.rs-2934995/v1
Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapySemantic proximity
Plasma Epstein-Barr virus DNA for the prediction of treatment response and disease progression in non-keratinizing differentiated nasopharyngeal carcinomaSemantic proximity
Spontaneous remission of residual post‐therapy plasma Epstein–Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large‐scale, big‐data intelligence platform‐based analysisSemantic proximity
The Clinical Utility of Plasma Epstein–Barr Virus DNA Assays in Nasopharyngeal CarcinomaSemantic proximity
The Dynamic Change in Plasma Epstein–Barr Virus DNA Load over a Long-Term Follow-Up Period Predicts Prognosis in Nasopharyngeal CarcinomaSemantic proximity
Nasopharyngeal carcinoma at the virology precision oncology nexus: decoding molecular alterations for early intervention and therapeutic innovationSemantic proximity
Nasopharyngeal Carcinoma at the Virology Precision Oncology Nexus: Decoding Molecular Alterations for Early Intervention and Therapeutic Innovation.Semantic proximity
Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinomaSemantic proximity
Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinomaSemantic proximity
Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinomaSemantic proximity
Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive populationSemantic proximity
Systematic comparison of plasma EBV DNA, anti‐EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinomaSemantic proximity
Select a neighboring publication to make it the new centre.